These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15648966)

  • 1. [An ultrasensitive C-reactive protein assay--a new parameter in cardiovascular risk].
    Dvoráková A; Poledne R
    Vnitr Lek; 2004 Nov; 50(11):852-7. PubMed ID: 15648966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.
    Jialal I; Devaraj S
    Am J Clin Pathol; 2001 Dec; 116 Suppl():S108-15. PubMed ID: 11993695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay.
    Jovicić S; Ignjatović S; Dajak M; Majkić-Singh N
    Clin Chem Lab Med; 2006; 44(2):228-31. PubMed ID: 16475913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CRP--a marker of a pro-inflammatory state and cardiovascular risk].
    Poledne R; Valenta Z; Pit'ha J
    Vnitr Lek; 2007 Apr; 53(4):391-5. PubMed ID: 17578172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of high-sensitivity C-reactive protein].
    Ueno H
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():137-41. PubMed ID: 16983765
    [No Abstract]   [Full Text] [Related]  

  • 8. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection.
    Guimarães MM; Greco DB; Figueiredo SM; Fóscolo RB; Oliveira AR; Machado LJ
    Atherosclerosis; 2008 Dec; 201(2):434-9. PubMed ID: 18359028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Ridker PM; Wilson PW; Grundy SM
    Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men.
    Jiménez MC; Rexrode KM; Glynn RJ; Ridker PM; Gaziano JM; Sesso HD
    J Am Heart Assoc; 2015 Sep; 4(9):e002073. PubMed ID: 26391131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome.
    Abu-Farha M; Abubaker J; Al-Khairi I; Cherian P; Noronha F; Kavalakatt S; Khadir A; Behbehani K; Alarouj M; Bennakhi A; Elkum N
    Cardiovasc Diabetol; 2016 Feb; 15():25. PubMed ID: 26850725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of High Sensitivity C-Reactive Protein in Cardiovascular Disease Detection.
    Castro AR; Silva SO; Soares SC
    J Pharm Pharm Sci; 2018; 21(1):496-503. PubMed ID: 30496036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of C-reactive protein: two high sensitivity methods compared.
    Dominici R; Luraschi P; Franzini C
    J Clin Lab Anal; 2004; 18(5):280-4. PubMed ID: 15356879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome in the prediction of cardiovascular events: the potential additive role of hsCRP and adiponectin.
    Santaniemi M; Ukkola O; Malo E; Bloigu R; Kesäniemi YA
    Eur J Prev Cardiol; 2014 Oct; 21(10):1242-8. PubMed ID: 23787794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease.
    Ridker PM
    Clin Chem; 2010 Jul; 56(7):1186-7. PubMed ID: 20360125
    [No Abstract]   [Full Text] [Related]  

  • 19. Proinflammatory status, genetics and atherosclerosis.
    Poledne R; Lorenzová A; Stávek P; Valenta Z; Hubáček J; Suchánek P; Pitha J
    Physiol Res; 2009; 58 Suppl 2():S111-S118. PubMed ID: 20131929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the Shimanami Health Promoting Program Study.
    Tabara Y; Osawa H; Kawamoto R; Tachibana-Iimori R; Yamamoto M; Nakura J; Miki T; Makino H; Kohara K
    J Clin Endocrinol Metab; 2008 Mar; 93(3):715-22. PubMed ID: 18160463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.